Abstract: A micro- or nanoparticular vesicle comprises at least a crosslinked hyaluronic acid (HA), wherein the crosslinked hyaluronic acid is crosslinked by a chemical crosslinking agent, and wherein the degree of modification of said crosslinked hyaluronic acid with said chemical crosslinking agent is less than 1.9 mole %. Also disclosed are a method of manufacturing such vesicles, compositions comprising such vesicles and their uses.

Abstract: Provided is an anti-aging agent for skin which contains, as an active component, an inositol derivative in which a monosaccharide or an oligosaccharide is bonded to inositol, in which a total amount of the monosaccharide or the oligosaccharide bonded to one inositol molecule is 2 or greater in terms of monosaccharide unit.

Abstract: Methods for producing refined xylan from a biomass solution, including: (i) providing a biomass solution, which comprises xylan; (ii) concentrating or separating said biomass solution to obtain a xylan concentrate comprising xylan and impurities; (iii) washing and/or extracting the xylan concentrate with a solvent to obtain refined xylan and a solvent stream comprising the solvent and impurities; and (iv) collecting the refined xylan.

Abstract: The invention concerns a process for the manufacture of an acylated polysaccharide which comprises. (a) reacting a polysaccharide with an acylating agent to produce an acylated polysaccharide and (b) washing the acylated polysaccharide with water containing from 0.05 to 15 mg/l Ca2+-ions (c) recovering the washed acylated polysaccharide and an aqueous phase containing carboxylic acid from step (b).

Abstract: The invention relates to a method for stabilising or reducing insulin resistance in patients having an obesity-related, metabolic disorder, the method comprising administering to the patient an effective amount of one or more human milk oligosaccharides (HMOs).

Abstract: Disclosed is a method for therapeutic management of hyperglycemia in mammals using compositions containing thymohydroquinone. More specifically, the invention discloses compositions containing thymohydroquinone for inhibiting the activity of the enzyme ?-glucosidase and increasing the cellular uptake of glucose by mammalian cells. The anti-oxidant, anti-inflammatory and anti-glycation effects of thymohydroquinone are also disclosed herein.

Abstract: Processes for converting lignocellulose to feedstock and downstream products are disclosed. The processes may include acid treatment of lignocellulose to produce a fermentation feedstock. In various instances, the processes include recovery or recycling of acid, such as recovery of hydrochloric acid from concentrated and/or dilute streams. Downstream products may include acrylic acid-based products such as diapers, paper and paper-based products, ethanol, biofuels such as biodiesel and fuel additives, and detergents.

Abstract: The invention relates to N-desulfated and optionally 2-O-desulfated glycosaminoglycan derivatives, wherein at least part of the adjacent diols and OH/NH2 have been converted into the corresponding aldehyde, which aldehydes have been then reduced to the corresponding alcohol. These products are endowed with heparanase inhibitory activity and anti-tumor activity. Said glycosaminoglycan derivatives are obtained from natural or synthetic glycosaminoglycan, preferably from unfractionated heparin, low molecular weight heparins (LMWHs), heparan sulfate or derivatives thereof. The invention further relates to the process for preparation of the same and further to their use as active ingredients of medicaments, also in combination with known established drugs or treatments. The present invention further relates to a process for breaking the C2-C3 linkage of glucosamine residues of a glycosaminoglycan by oxidation of said glycosaminoglycan.

Abstract: Immune function of an animal can be modulated by administration of a composition that includes beta glucan. The beta glucan can be derived from Euglena, which provides a form of beta glucan that is different from other organisms, where the beta glucan is predominantly unbranched beta-(1,3)-glucan. Beta glucan can also be complexed with a metal, such as zinc, and/or can combined with an animal feed component to form an animal feed composition. Use of such compositions can improve the well being of an animal, and may augment or even replace the use of antibiotics in certain circumstances.

Abstract: This disclosure relates to synthetic oligosaccharide subunits of the Pseudomonas exosaccharide Psi and uses thereof, e.g., for epitope mapping of anti-Psl antibodies, for identification of anti-Psl antibodies, and for use as vaccines. In one aspect a synthetic oligosaccharide subunit of a Pseudomonas aeruginosa Psl oligosaccharide is provided, comprising the trisaccharide of formula I.

Abstract: One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

Abstract: The application describes compositions that include maltosyl-isomalto-oligosaccharides with a desirable mass average molecular weight distribution. In some cases, the compositions can contain at least 3% mannitol.

Abstract: This invention relates to a method and composition for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation.

Abstract: In order to obtain a crosslinked cellulose without derivatization, a polymer according to an embodiment of the present disclosure is a polymer having a structure in which cellulose substantially represented by the following formula (c1) is crosslinked with a polyfunctional epoxy compound: wherein in the formula (c1), n represents an integer of 2 or more.

Abstract: Provided herein are common starch-based and waxy starch-based hydrolyzed starches. The hydrolyzed starches described herein demonstrate desirable properties over existing hydrolyzed starches for food applications, including but not limited to, dairy, ready-to-eat cereal coatings, clean-label confectionary products, nutritional and cereal bars, crumb chocolate, infant and/or elderly nutrition.

Abstract: Provided herein are common starch-based and waxy starch-based hydrolyzed starches. The hydrolyzed starches described herein demonstrate desirable properties over existing hydrolyzed starches for food applications, including but not limited to, dairy, ready-to-eat cereal coatings, clean-label confectionary products, nutritional and cereal bars, crumb chocolate, infant and/or elderly nutrition.

Abstract: A process is described for preparing a composition in the form of an emulsion that includes a high concentration of one or more avermectins. This process can include partitioning the avermectin between an active phase, including at least one glycol, and an oily phase of the emulsion. A composition thus obtained, is also described that can be used in the treatment of dermatological disorders such as rosacea.

Abstract: The application relates to synthetic compositions containing one or more human milk oligosaccharides for regulating satiety or reducing propensity to obesity.

Abstract: The disclosure relates to compositions and methods for treatment, such as inducing regression or inhibiting growth, of tumors in a patient such as a human. Use of gemcitabine, including in self-emulsifying orally administered dosage forms for these purposes is described. Gemcitabine is orally administered in a metronomic manner, which involves repeatedly administering a therapeutic amount of gemcitabine, being a fraction of the maximum tolerated dose, over an extended period of time, preferably on a non-interrupted schedule of weeks, months, or indefinitely.

Abstract: The invention relates to a synthetic composition comprising one or more human milk monosaccharides and/or one or more human milk oligosaccharides for use in reducing intestinal permeability, endotoxemia and/or low-grade inflammation in patients with metabolic disorders.